Efthymios Papageorgiou1, Bernhard Boser, Mekhail Anwar2
13:30 - 15:00 | Mon 29 Oct | Ambassador A | A3L-B.1
A novel fluorescence contact imaging system is used to image mouse tumor tissue labeled in vivo using a custom fluorescence imaging agent, Trastuzumab-IR700DX. The HER2+ tumor targeted by the imaging agent is 4.5±1.1 brighter than the HER2- tumor that is not targeted. HER2+ tumor is distinguished from HER2- tumor and healthy tissue with a short integration time of 70 ms and a high SNR of 33 dB.